December 16, 2015 / 6:08 PM / 2 years ago

BUZZ-Acasti Pharma Inc: FDA gives positive feedback on lead drug

** Drugmaker's U.S.-listed shares surge 60 pct to $2.57 in heavy trading, set for best day since debut

** FDA gives positive feedback to the proposed development pathway of Acasti's lead drug, CaPre, to treat high levels of triglycerides that can cause heart disease

** Company's proposed application uses data from studies iit did not conduct and relies on findings available on another FDA-approved drug

** Such applications result in much less costs and a faster route to drug approval, compared to a traditional development path

** Acasti will also conduct another study to compare CaPre with another FDA-approved prescription drug to establish scientific difference between the two

** About 1.3 mln shares traded, about 60 times 25-day avg

** Up to Tuesday's close, stock had fallen about 68 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below